Current Clinical Trials

Studies listed below are currently open to accept new study patients. If you believe you might meet the baseline criteria, or would simply like more information, please contact us.

Condition Study Name Criteria Additonal Information
Atrial Fibrillation Atrial Fibrillation
  • Atrial fibrillation or flutter, paroxysmal or sustained not due to a reversible cause, and eligible to receive anticoagulation therapy

  • Patient must satisfy one or both of the following categories of risk factors:
    • Age ≥75 years at the time of screening
    • History of a clinical symptomatic stroke of any type.
  • OR

  • Patient must satisfy two or more of the following categories of risk factors:
    • Age between 65 and 74 years
    • Hypertension
    • Diabetes mellitus
    • Atherosclerotic vascular disease meeting one or more of the following criteria: a) Lower extremity PAD or b) prior major vascular amputation, peripheral bypass, or peripheral percutaneous
    • And/Or CAD, MI, CABG, PCI
  • Does not have a history of any of the following only if within 3 months of randomization: primary hemorrhagic stroke, hemorrhagic transformation of an ischemic stroke, subarachnoid hemorrhage, subdural hematoma, spinal cord hemorrhage.

  • Does not have any condition other than AF that requires chronic anticoagulation
  • Does not have current active liver disease (eg, acute hepatitis, known cirrhosis), including participants receiving antiviral treatment for hepatitis.
  • There will be about 20 office visits over about 4 years
  • Patients may be compensated up to $70 per office visit
  • Patients will receive lab tests, diabetes medications, physical exams, and study related care at no cost
  • Patients will be directed to their own doctor for normal care/non-study related health concerns
Cardiovascular Disease Cardiovascular Outcomes
  • Age above or equal to 18 years
  • eGFR ≥15 and < 60 mL/min/1.73 m2 (using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation).
  • Evidence of ASCVD by one or more of the following within the last 5 years:
    • Coronary heart disease defined as at least one of the following:
      • Documented history of MI, prior coronary revascularization procedure, or ≥50% stenosis in major epicardial coronary artery documented by cardiac catheterisation or CT coronary angiography
    • Cerebrovascular disease defined as at least one of the following:
      • Prior stroke of atherosclerotic origin, prior carotid artery revascularisation procedure, or ≥50% stenosis in carotid artery documented by X-ray angiography, MR angiography, CT angiography or Doppler ultrasound.
    • Symptomatic peripheral artery disease (PAD) defined as at least one of the following:
      • Intermittent claudication with an ankle-brachial index (ABI) ≤ 0.90 at rest, intermittent claudication with a ≥50% stenosis in peripheral artery (excluding carotid) documented by X-ray angiography, MR angiography, CT angiography or Doppler ultrasound, prior peripheral artery (excluding carotid) revascularisation procedure, or lower extremity amputation at or above ankle due to atherosclerotic disease (excluding e.g. trauma or osteomyelitis).
  • No current (or within 90 days of visit 1) chronic or intermittent haemodialysis or peritoneal dialysis.
  • No myocardial infarction, stroke, hospitalisation for unstable angina pectoris, or transient ischaemic attack within 60 days
  • No history of inflammatory bowel disease that has been clinically active during the last 12 months
  • Patients will be directed to PCP for normal care/non-study related health concerns
  • Patients will receive study medication at no cost during the course of the study
  • Patients will receive lab tests, physical exams, and study related care at no cost
  • Patients will receive reimbursement of $50 per completed office visit and $15 per completed phone visit for participating
  • The study involves about 18 office visits over approximately 4 years 
Obesity Overweight Adults
  • Have a body mass index (BMI) ≥27.0 kilogram/square meter (kg/m ²)
  • Are either
    • individuals ≥40 years of age with established cardiovascular disease (CVD).
      • CVD is defined as meeting at least one of the following:
        • Coronary artery disease
        • Cerebrovascular disease
    • Peripheral arterial disease OR
    • individuals without established CVD but have the presence of cardiovascular (CV) risk factors (primary prevention)
      • women 55-69 years of age or men 50-64 years of age with at least 3 risk factors like tobacco use, dyslipidemia, hypertension at screening, or
      • women ≥70 years of age or men, ≥65 years of age with at least 2 risk factors at screening. Are on a stable treatment of at least 1 antihyperglycemic medication, for at least 3 months
  • Do not have type 1 or type 2 diabetes
  • Do not have history of ketoacidosis, or hyperosmolar state/coma
  • Do not have class IV heart failure
  • Are not using or have not used a GLP-1 within 3 months
  • There will be about 27 study visits over about 5 years and 5 months
  • Patients will receive lab tests, diabetes medications, physical exams, and study related care at no cost
  • Patients will be directed to their own doctor for normal care/non-study related health concerns
Obesity and Cardiovascular Disease Obesity and Cardiovascular Disease
  • 55 years of age or older
  • Body mass index (BMI) ≥ 30
    1. Established CVD as evidenced by at least one of the following: Prior myocardial infarction, prior stroke (ischemic or hemorrhagic stroke), or Symptomatic peripheral arterial disease (PAD)
  • If diabetic:
    • Diagnosed with type 2 diabetes ≥ 180 days ago
    • HbA1c 7%-10%
  • No planned coronary, carotid or peripheral artery revascularization
  • Not being treatmed with any glucagon-like peptide-1 (GLP-1) receptor agonist (RA) or a medication with GLP-1 activity within 90 days
  • No chronic or intermittent hemodialysis or peritoneal dialysis
  • There will be about 22 study visits over about 3 years
  • Patients may be compensated up to $1,100.00 if all visits are completed
  • Patients will receive lab tests, diabetes medications, physical exams, and study related care at no cost
  • Patients will be directed to their own doctor for normal care/non-study related health concerns
Parkinson's Disease Parkinson's Disease (PD) - Online Study
  • Male or female over the age of 18
  • Diagnosis of Parkinson’s disease
  • Has Internet access to provide data online

For more information please visit:  www.foxinsight.org/clinic

  • Surveys on health-related topics to be completed every 3 months for 5 years
  • Optional, one-time surveys and sub-studies including genetic testing and counseling at no cost
  • Appointment reminders and physician reports online for patients
Type 2 Diabetes Type 2 Diabetes on Metformin
  • 18 years of age or older
  • Diagnosed with type 2 diabetes ≥ 180 days ago
  • Stable daily dose(s) ≥ 90 days of any of the following antidiabetic drug(s) or combination regimen(s) at effective or maximum tolerated dose: metformin with or without an SGLT2 inhibitor.
  • Do not have renal impairment
  • No treatment with any medication for the indication of diabetes or obesity other than metformin with or without SGLT2 inhibitor within 90 days
  • No planned (during the study period) obesity treatment with surgery or a weight loss device.
  • Patients will remain on their current diabetes medication regardless of treatment group
  • There will be about 14 office visits and 7 phone visits over about 18 months
  • Patients may be compensated up to $55 per office visit and $25 per phone visit if all visits are completed
  • Patients will receive lab tests, diabetes medications, physical exams, and study related care at no cost
  • Patients will be directed to their own doctor for normal care/non-study related health concerns
Type 2 Diabetes Type 2 Diabetes on Metformin
  • 18 years of age or older
  • Diagnosed with type 2 diabetes ≥ 180 days ago
  • Stable daily dose(s) ≥ 90 days of any of the following antidiabetic drug(s) or combination regimen(s) at effective or maximum tolerated dose: metformin with or without an SGLT2 inhibitor.
  • Does not have renal impairment
  • No treatment with any medication for the indication of diabetes or obesity other than metformin with or without SGLT2 inhibitor within 90 days
  • No planned (during the study period) obesity treatment with surgery or a weight loss device.
  • Patients will remain on their current diabetes medication regardless of treatment group
  • There will be about 19 office visits and 8 phone visits over about 18 months
  • Patients may be compensated up to $55 for office visits and $20 for phone visits if all visits are completed
  • Patients will receive lab tests, diabetes medications, physical exams, and study related care at no cost
  • Patients will be directed to their own doctor for normal care/non-study related health concerns